Oncology EMRs: Buyer Beware, an Interview with Marty Neltner

Podcast

The Obama administration is pushing for universal EMR adoption. Sounds like a good idea. But are EMRs ready for prime time?

Marty Neltner

Marty Neltner

Clinicians often cite enhanced quality care, patient safety, and increased efficiencies as rationale for implementing electronic medical records (EMRs) in the community oncology setting. Those are strong reasons for interest in medical software. However, in a climate where reimbursements are falling and physician reimbursements are flat, the cost and difficulty of an EMR can increasingly seem to be a barrier. Oncologists and business executives are particularly aware of the ongoing decreases in Medicare reimbursements and significant coding changes in years since the passage of the Medicare Modernization Act of 2003 (MMA).

The Obama administration is pushing for an interoperable health information system; a timetable of incentives; the pressure is on and the move toward electronic oncology offices is ineluctable.  So, will EMRs help oncologists enhance quality of care by facilitating better data aggregation and sharing and increase revenue by enhancing office management efficiencies?

According to nationally recognized healthcare specialist, Marty Neltner, conceptually EMRs are a good thing, but the current designs do not deliver the necessary functions for today’s oncologist.

-Interviewed by Ron Piana

Up next: A care-giver's perspective on the EMR conundrum.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.